Oncology News and Research

RSS
Researchers one step closer to understanding development of glioblastoma

Researchers one step closer to understanding development of glioblastoma

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Accuray, Lancaster announces commercial availability of InCise MLC for CyberKnife M6 System

Accuray, Lancaster announces commercial availability of InCise MLC for CyberKnife M6 System

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Study reveals how household net worth affects breast cancer care

Study reveals how household net worth affects breast cancer care

Johns Hopkins scientists identify genetic pathway that may spur cancer cell growth in children

Johns Hopkins scientists identify genetic pathway that may spur cancer cell growth in children

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

Fox Chase Cancer Center's Radiation Oncology Department earns ACR accreditation

Fox Chase Cancer Center's Radiation Oncology Department earns ACR accreditation

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Bayer expands patient assistance program for intrauterine devices

Bayer expands patient assistance program for intrauterine devices

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.